



Receipt date: 02/02/2007

10563944 - GAU: 1648

Equivalent of Form PTO/SB/08A (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
Sheet 1 of 2				Examiner Name	To Be Assigned
				Attorney Docket Number	1700.0670000/BJD/WBC

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	US1	4,912,094	03/27/1990	Myers <i>et al.</i>	
	US2	5,939,598	08/17/1999	Kucherlapati <i>et al.</i>	
	US3	6,194,388	02/27/2001	Krieg <i>et al.</i>	
	US4	6,207,646	03/27/2001	Krieg <i>et al.</i>	
	US5	6,239,116	05/29/2001	Krieg <i>et al.</i>	
	US6	6,406,705	06/18/2002	Davis <i>et al.</i>	
	US7	6,429,199	08/06/2002	Krieg <i>et al.</i>	
	US8	2003/0091599 A1	05/15/2003	Davis <i>et al.</i>	
	US9	6,653,292	11/25/2003	Krieg <i>et al.</i>	
	US10	2003/0224010 A1	12/04/2003	Davis <i>et al.</i>	
	US11	2004/0030118 A1	02/12/2004	Wagner <i>et al.</i>	
	US12	2004/0234512 A1	11/25/2004	Wagner <i>et al.</i>	
	US13	2004/0235777 A1	11/25/2004	Wagner <i>et al.</i>	
	US14	2004/0235778 A1	11/25/2004	Wagner <i>et al.</i>	
	US15	2005/0043529 A1	02/24/2005	Davis <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	WO 98/50071 A1	11/12/1998	Chiron Corporation		
	FP2	WO 99/29723 A1	06/17/1999	Pentamer Pharmaceuticals		
	FP3	WO 00/23955 A1	04/27/2000	The Government of the United States of America		
	FP4	WO 00/32227 A2	06/08/2000	Cytos Biotechnology AG		
	FP5	WO 00/37610 A2	06/29/2000	Boyce Thompson Institute for Plant Research at Cornell		
	FP6	WO 00/39304 A2	07/06/2000	Chiron Corporation		
	FP7	WO 00/62800 A2	10/26/2000	Smithkline Beecham Biologicals SA		
	FP8	WO 01/22972 A2	04/05/2001	University of Iowa Research Foundation; Coley Pharmaceutical GMBH		

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

603848_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

Equivalent of Form PTO/SB/08A (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				\$371 Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	1700.0670000/BJD/WBC

	FP9	WO 01/56603 A1	08/09/2001	Tanox, Inc.		
--	-----	----------------	------------	-------------	--	--

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ⁴ Kind Code ³ (if known)				
	FP10	WO 01/85208 A2	11/15/2001	Cytos Biotechnology AG		
	FP11	WO 02/10416 A1	02/07/2002	The Crown in the Right of the Queensland Department of Health		
	FP12	WO 02/056905 A2	07/25/2002	Cytos Biotechnology AG		
	FP13	WO 03/024481 A2	03/27/2003	Cytos Biotechnology AG		

Examiner Signature	/E.L./	Date Considered	10/11/2008
-----------------------	--------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

603848 1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /EL/



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				\$371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	1	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL1	Abreu, M.T., and Arditi, M. J., "Innate Immunity and Toll-like Receptors: Clinical Implications of Basic Science Research," <i>Pediatrics</i> 144:421-9, American Academy of Pediatrics (April 2004)	
	NPL2	Alexopoulou, L., <i>et al.</i> , "Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3," <i>Nature</i> 413:732-8, Nature Publishing Group (2001)	
	NPL3	Aliprantis, A.O., <i>et al.</i> , "Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-like Receptor-2," <i>Science</i> 285:736-9, American Association for the Advancement of Science (1999)	
	NPL4	Arlian, L.G., "Dust Mites: Update on Their Allergens and Control," <i>Current Allergy and Asthma Reports</i> 1:581-586, Current Science Inc. (2001)	
	NPL5	Bachmann, M.F., and Zinkernagel, R.M., "Neutralizing Antiviral B Cell Responses," <i>Annu. Rev. Immunol.</i> 15:235-270, Annual Reviews (1997)	
	NPL6	Bachmann, M.F., and Zinkernagel, R.M., "The influence of virus structure on antibody responses and virus serotype formation," <i>Immunol. Today</i> 17:553-558, Elsevier Science Publishers (1996)	
	NPL7	Bannon, G.A., <i>et al.</i> , "Engineering, Characterization and in vitro Efficacy of the Major Peanut Allergens for Use in Immunotherapy," <i>Int. Arch. Allergy Immunol.</i> 124:70-72, Karger (2001)	
	NPL8	Beutler, B., "Toll-like receptors: how they work and what they do," <i>Curr. Opin. Hematol.</i> 9:2-10, Lippincott Williams And Wilkins (January 2002)	
	NPL9	Biragyn, A., <i>et al.</i> , "Toll-like Receptor 4-Dependent Activation of Dendritic Cells by β -Defensin 2," <i>Science</i> 298:1025-9, American Association for the Advancement of Science (November 2002)	

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

If you need assistance in completing the form, call 1-800-PATENT (1-800-768-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	2	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL10	Clarke, A.H., <i>et al.</i> , "Murine Allergic Respiratory Responses to the Major House Dust Mite Allergen Der p 1," <i>Int. Arch. Allergy Immunol.</i> 120:126-134, Karger (1999)	
	NPL11	Cohen, P.A., <i>et al.</i> , "CD4+ T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens," <i>Cancer Res.</i> 54:1055-8, American Association for Cancer Research (1994)	
	NPL12	DeClercq, E., "Interferon Induction by Polynucleotides, Modified Polynucleotides, and Polycarboxylates," <i>Meth. Enzymol.</i> 78:227-236, Academic Press (1981)	
	NPL13	Diebold, S.S., <i>et al.</i> "Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA," <i>Science</i> 303:1529-31, American Association for the Advancement of Science (March 2004)	
	NPL14	Engleman, E.G., "Dendritic cells: Potential role in cancer therapy," <i>Cytotechnology</i> 25:1-8, Kluwer Academic Publishers (1997)	
	NPL15	Eriksson, T.L., <i>et al.</i> , "T cell responses to recombinant isoforms, synthetic peptides and a mutant variant of Lep d 2, a major allergen from the dust mite <i>Lepidoglyphus destructor</i> ," <i>Clin. Exp. Allergy</i> 31:1881-1890, Blackwell Scientific Publications (2001)	
	NPL16	Fehr, T., <i>et al.</i> , "Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies," <i>J. Exp. Med.</i> 185:1785-1792, The Rockefeller University Press (1997)	
	NPL17	Fernandes, I., <i>et al.</i> , "Synthetic Lipopeptides Incorporated in Liposomes: In Vitro Stimulation of the Proliferation of Murine Splenocytes and In Vivo Induction of an Immune Response Against a Peptide Antigen," <i>Mol. Immunol.</i> 34:569-576, Pergamon Press (1997)	
	NPL18	Fitchen, J., <i>et al.</i> , Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response," <i>Vaccine</i> 13:1051-7, Elsevier Science (1995)	

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	3	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL19	Gerber, S., <i>et al.</i> , "Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with Escherichia coli Heat-Labile Enterotoxin Mutant R192G or CpG DNA," <i>J. Virol.</i> 75:4752-60, American Society for Microbiology (2001)	
	NPL20	Geysen, H.M., <i>et al.</i> , "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 81:3998-4002, National Academy of Sciences (1984)	
	NPL21	Gluckman, J. C., <i>et al.</i> , "In vitro generation of human dendritic cells and cell therapy," <i>Cytokines Cell. Mol. Ther.</i> 3:187-96, Martin Dunitz Ltd. (1997)	
	NPL22	Hayashi, F., <i>et al.</i> , "The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5," <i>Nature</i> 410:1099-103, Nature Publishing Group (2001)	
	NPL23	Heil, F.H., <i>et al.</i> , "Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8," <i>Science</i> 303:1526-9, American Association for the Advancement of Science (March 2004)	
	NPL24	Hemmi, H., <i>et al.</i> , "A Toll-like receptor recognizes bacterial DNA," <i>Nature</i> 408: 740-5, Nature Publishing Group (2000)	
	NPL25	Ioannou, X.P., <i>et al.</i> , "CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein," <i>Vaccine</i> 21:127-37, Elsevier Science (November 2002)	
	NPL26	Johnson, D.A., <i>et al.</i> , "3-O-Desacyl Monophosphoryl Lipid A Derivatives: Synthesis and Immunostimulant Activities," <i>J. Med. Chem.</i> 42:4640-649, American Chemical Society (1999)	
	NPL27	Justice, J.P., <i>et al.</i> , "Ragweed-induced expression of GATA-3, IL-4, and IL-5 by eosinophils in the lungs of allergic C57BL/6J mice," <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> 282:L302-9, The American Physiological Society (February 2002)	

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	4	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL28	Kaisho, T., and Akira, S., "Toll-like receptors as adjuvant receptors," <i>Biochim. Biophys. Acta</i> 1589:1-13, Elsevier Pub. Co. (February 2002)	
	NPL29	Kircher, M.F., <i>et al.</i> , "Vβ18.1 ⁺ and Va2.3 ⁺ T-cell subsets are associated with house dust mite allergy in human subjects," <i>J. Allergy Clin. Immunol.</i> 109:517-23, Mosby (March 2002)	
	NPL30	Kozlovskaya, T.M., <i>et al.</i> , "RNA Phage Qβ Coat Protein as a Carrier for Foreign Epitopes," <i>Intervirology</i> 39:9-15, Karger (1996)	
	NPL31	Kuramoto, E., <i>et al.</i> , "Oligonucleotide Sequences Required for Natural Killer Cell Activation," <i>Jpn. J. Cancer Res.</i> 83:1128-31, Japanese Cancer Association (1992)	
	NPL32	Levy, H.B., "Induction of Interferon in Vivo and in Vitro by Polynucleotides and Derivatives, and Preparation of Derivatives," <i>Meth. Enzymol.</i> 78:242-51, Academic Press (1981)	
	NPL33	Li, X.M., <i>et al.</i> , "A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses," <i>J. Allergy Clin. Immunol.</i> 106:150-58, Mosby (2000)	
	NPL34	Marshall, J.D., <i>et al.</i> , "Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy," <i>J. Allergy Clin. Immunol.</i> 108:191-97, Mosby (2001)	
	NPL35	Moss, R.B., <i>et al.</i> , "In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides," <i>Vaccine</i> 18:1081-7, Elsevier Science (2000)	
	NPL36	O'Hagan, D.T., "Recent Developments in Vaccine Delivery Systems," <i>Curr Drug Targets Infect Disord</i> 1:273-86, Bentham Science Publishers (2001)	

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

If you need assistance in completing this form, call 1-800-Patent-9119 (1-800-760-9119) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	5	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL37	Persing, D.H., <i>et al.</i> , "Taking toll: lipid A mimetics as adjuvants and immunomodulators," <i>Trends Microbiol.</i> 10:32-37, Elsevier Trends Journals (October 2002)	
	NPL38	Poltorak, A., <i>et al.</i> , "Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene," <i>Science</i> 282:2085-8, American Association for the Advancement of Science (1998)	
	NPL39	Przetak, M., <i>et al.</i> , "Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice," <i>Vaccine</i> 21:961-970, Elsevier Science (February 2003)	
	NPL40	Redman, T.K., <i>et al.</i> , "Pulmonary Immunity to Ragweed in a Beagle Dog Model of Allergic Asthma," <i>Exp. Lung Res.</i> 27:433-51, Taylor & Francis (2001)	
	NPL41	Renkvist, N., <i>et al.</i> , "A listing of human tumor antigens recognized by T cells," <i>Cancer. Immunol. Immunother.</i> 50:3-15, Springer Verlag (2001)	
	NPL42	Romagnani, S., "The Th1/Th2 paradigm," <i>Immunol. Today</i> 18:263-66, Elsevier Science Publishers (1997)	
	NPL43	Santeliz, J.V., <i>et al.</i> , "Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma," <i>J. Allergy Clin. Immunol.</i> 109:455-62, Mosby (March 2002)	
	NPL44	Schnare, M., <i>et al.</i> , "Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88," <i>Curr. Biol.</i> 10:1139-42, Cell Press (2000)	
	NPL45	Schwarz, K., <i>et al.</i> , "Role of Toll-like receptors in costimulating cytotoxic T cell responses," <i>Eur. J. Immunol.</i> 33:1465-470, VCH Verlagsgesellschaft (June 2003)	

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

If you need assistance in completing the form, call 1-800-PATENT-9119 (1-800-786-9119) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	6	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL46	Shampain, M.P., <i>et al.</i> , "An Animal Model of Late Pulmonary Responses to Alternaria Challenge," <i>Am. Rev. Respir. Dis.</i> 126:493-98, American Lung Association (1982)	
	NPL47	Speiser, D.E., <i>et al.</i> , "Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy," <i>J. Exp. Med.</i> 186:645-53, The Rockefeller University Press (1997)	
	NPL48	Steinman, R.M., "Dendritic cells and immune-based therapies," <i>Exp. Hematol.</i> 24:859-62, Elsevier Science (1996)	
	NPL49	Storni, T., <i>et al.</i> , "Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles," <i>J. Immunol.</i> 168:2880-6, The American Association of Immunologists (March 2002)	
	NPL50	Torrence, P.F., "Preparation of a Synthetic Polynucleotide Interferon Inducer," <i>Meth. Enzymol.</i> 78:326-31, Academic Press (1981)	
	NPL51	Underhill, D.M., <i>et al.</i> , "The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens," <i>Nature</i> 401:811-5, Nature Publishing Group (1999)	
	NPL52	Vabulas, R.M., <i>et al.</i> , "HSP70 as Endogenous Stimulus of the Toll/Interleukin-1 Receptor Signal Pathway," <i>J. Biol. Chem.</i> 277(17):15107-12, The American Society for Biochemistry and Molecular Biology (April 2002)	
	NPL53	Vailes, L.D., <i>et al.</i> , "IgE and IgG antibody responses to recombinant Alt a 1 as a marker of sensitization to Alternaria in asthma and atopic dermatitis," <i>Clin. Exp. Allergy</i> 31:1891-95, Blackwell Scientific Publications (2001)	
	NPL54	Vailes, L.D., <i>et al.</i> , "Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products," <i>J. Allergy Clin. Immunol.</i> 107:641-6, Mosby (2001)	

Examiner Signature	/E.L./	Date Considered	10/11/2008
--------------------	--------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,944 (U.S. Nat'l Phase of Int'l Appl. No. PCT/EP04/07679)
				§371 Filing Date	May 31, 2006
				First Named Inventor	BACHMANN, Martin F.
				Art Unit	1644
				Examiner Name	To Be Assigned
Sheet	7	of	7	Attorney Docket Number	1700.0670000/BJD/WBC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL55	Van Schooten, W.C., <i>et al.</i> , "Biological properties of dendritic cells: implications to their use in the treatment of cancer," <i>Molecular Medicine Today</i> 3:254-60, Elsevier Trends Journals (1997)	
	NPL56	Yamamoto, S., <i>et al.</i> , "The discovery of immunostimulatory DNA sequence," <i>Springer Semin. Immunopathol.</i> 22:11-19, Springer Verlag (2000)	
	NPL57	Yuan, T.T., <i>et al.</i> , "Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen," <i>J. Virol.</i> 73:10122-8, American Society for Microbiology (1999)	
	NPL58	Zhang, D., <i>et al.</i> , "A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria," <i>Science</i> 303:1522-6, American Association for the Advancement of Science (March 2004)	

Examiner Signature	/Emily Le/	Date Considered	10/11/2008
--------------------	------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.